Insulin aspart

Biocon Biologics Successfully Completes Integration of Viatris’ Biosimilar Business in 31 Countries in Europe

Retrieved on: 
Thursday, November 30, 2023
Insulin glargine, BBL, Acquisition, Health, White paper, Etanercept, Ophthalmology, Insulin aspart, Patient, Adalimumab

BENGALURU, India, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the integration of the Viatris’ biosimilars business in 31 European countries has been successfully completed.

Key Points: 
  • BENGALURU, India, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the integration of the Viatris’ biosimilars business in 31 European countries has been successfully completed.
  • In Europe, Biocon Biologics portfolio includes 7 biosimilars: Insulin Aspart and Insulin Glargine, Bevacizumab, Pegfilgrastim, Trastuzumab, Adalimumab, and Etanercept.
  • At a global level, Biocon Biologics has a robust pipeline of 20 assets for diabetology, oncology, immunology, ophthalmology, and bone health.
  • Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd, said: “The integration of the Viatris’ biosimilar business in Europe ahead of schedule is another important milestone for Biocon Biologics in our journey as a global biosimilars leader.

Meitheal Announces Exclusive Commercial Licensing Agreement for Insulin Biosimilars in the U.S.

Retrieved on: 
Thursday, September 21, 2023
Biotechnology, Diabetes, Health, Pharmaceutical, Medical Supplies, Insulin glargine, Insulin, Partnership, Insulin lispro, Medication, Patient, Insulin aspart, NKF, FDA, Pharmaceutical industry, Communal work

THDB and NKF entered into strategic cooperation and will be jointly responsible for the development and supply of the three products.

Key Points: 
  • THDB and NKF entered into strategic cooperation and will be jointly responsible for the development and supply of the three products.
  • Upon approval, THDB, NKF and Meitheal will receive royalties on all product sales in the United States.
  • “This collaboration reinforces the strength of NKF’s partnership with Meitheal and demonstrates our commitment to innovation and continued investment in our portfolio companies,” said Eric Tang, President of NKF.
  • “We look forward to bringing these three products one step closer to patients through this strategic partnership.”

California Selects Civica Rx as Its Insulin Manufacturing Partner

Retrieved on: 
Saturday, March 18, 2023
Public Policy, Government, Pharmaceutical, State, Local, Managed Care, Health, Diabetes, Healthcare Reform, Hospitals, Insulin, Inc., Partnership, Insulin lispro, Patient, Risk, Insulin aspart, Pharmaceutical industry, Civica, Insulin glargine

Civica Inc. (Civica, Civica Rx) today announced it will manufacture insulins for the State of California’s CalRx Biosimilar Insulin Initiative as part of its insulin manufacturing work.

Key Points: 
  • Civica Inc. (Civica, Civica Rx) today announced it will manufacture insulins for the State of California’s CalRx Biosimilar Insulin Initiative as part of its insulin manufacturing work.
  • “California’s partnership with Civica is a game changer,” said California Governor Gavin Newsom.
  • Civica and CalRx have the mutual goal of ensuring access to affordable insulins that have single, low transparent prices.
  • The next phase of this partnership is assessing options for the standup of an insulin manufacturing facility in California and further efforts to disrupt the insulin market and provide additional benefits for patients who depend on this life saving drug.

SaverOne Presents Business Update with YoY Revenue Growth of 127% for the First Nine Months of 2022

Retrieved on: 
Wednesday, December 21, 2022
TASE, Bank, VRU, Keshet, Truck, Research, ADS, ADSS, Israel Airports Authority, NIS, Marketing, Detection, American depositary receipt, DDPS, Advanced driver-assistance systems, Growth, First International Bank of Israel, FedEx, Electronics, MOU, Logistics, ADAS, Transport, Accident, Osem, Traction, OEM, POC, Saudi Readymix Concrete Company, Renewable energy, Cryptocurrency, Mobile phone, Marcus Brimage, Insulin aspart, Iveco

PETAH TIKVAH Israel, Dec. 21, 2022 /PRNewswire/ --  SaverOne 2014 Ltd. (Nasdaq: SVRE) (TASE: SVRE), a company developing and deploying transportation safety and advanced driver-assistance systems (ADAS) technologies and solutions, today presented its results for the nine month period ended September 30, 2022 and presented recent business updates.

Key Points: 
  • Strong revenue growth with revenues of NIS 754,000 (~$213,000), an increase of 127% year-over-year compared with NIS 332,000 (~$94,000) in the same period last year.
  • It is noted that SaverOne is in its early revenue growth stage with primary focus on sales and marketing and investment in R&D and advancing its technology.
  • Net loss was NIS 19,742,000 (~$5,572,000) for the nine months ended September 30, 2022, compared to NIS 19,203,000 (~$5,420,000) for the nine months ended September 30, 2021.
  • Cash and cash equivalents and short-term bank deposits as of September 30, 2022, amounted to NIS 32.1 million (~$9.1 million).

Bigfoot Biomedical Announces Insulin Compatibility Expansion to Support Insulin Affordability and Flexibility for People with Diabetes

Retrieved on: 
Monday, November 7, 2022
Biotechnology, Insurance, Pharmaceutical, Health, Diabetes, Medical Devices, Professional Services, Health Insurance, Insulin, Medicare, Biomedicine, Bigfoot Biomedical, FDA, Bigfoot, Population, NYSE, Medicaid, Insulin aspart, CEO, Walmart, Novo Nordisk, CGM, Diabetes, NVO, Technology, Club, Insurance, American Diabetes Association, Pharmaceutical industry, Facebook, Lilly, Insulin lispro

It is a critical part of our mission, said Jeffrey Brewer, CEO of Bigfoot Biomedical.

Key Points: 
  • It is a critical part of our mission, said Jeffrey Brewer, CEO of Bigfoot Biomedical.
  • Our expansion of compatibility to include additional insulin brands will make it easier for Bigfoot to support a broader population of people with insulin-requiring diabetes and will give Bigfoot Unity users greater flexibility to switch between insulin brands when they have a change in insurance.
  • This news marks an important moment in time for Bigfoot as we strive to make insulin diabetes management tools more accessible for people who need them.
  • Bigfoot Biomedical was founded by a team of people with personal connections to Type 1 and Type 2 diabetes.

SaverOne Protection System Installed in NovoLog Pharmaceutical Delivery Trucks

Retrieved on: 
Tuesday, September 13, 2022
Risk, Safety, COVID-19, Accident, TASE, Intention, Company, Life, Intellectual property, Private Securities Litigation Reform Act, Environment, U.S. Securities and Exchange Commission, Public expenditure, Government, Forward-looking statement, CEO, Technology, Solution, Transport, National Highway Traffic Safety Administration, NASDAQ, OEM, Insurance, Research, Security (finance), Prospectus, Patent, Death, Risk management, Mobile phone, EU, Insulin aspart

PETAH TIKVAH, Israel, Sept. 13, 2022 /PRNewswire/ -- SaverOne 2014 Ltd. (NASDAQ: SVRE) (TASE: SVRE), a technology company engaged in transportation safety solutions, today announced that SaverOne has penetrated the pharmaceutical delivery vertical, installing an initial 10 SaverOne systems on Novolog delivery trucks. The potential is hundreds of delivery trucks in Israel. Novolog is a leading Israeli healthcare company, with a focus on pharmaceutical and medical device distribution and logistics.

Key Points: 
  • PETAH TIKVAH, Israel, Sept. 13, 2022 /PRNewswire/ -- SaverOne 2014 Ltd. (NASDAQ: SVRE) (TASE: SVRE),a technology company engaged in transportation safety solutions, today announced that SaverOne has penetrated the pharmaceutical delivery vertical, installing an initial 10 SaverOne systems on Novolog delivery trucks.
  • Novolog is a leading Israeli healthcare company, with a focus on pharmaceutical and medical device distribution and logistics.
  • We are pleased to be working with NovoLog in this critical area, which publicly demonstrates a very important use-case for our technology.
  • We see the SaverOne system as a key solution to lower some significant potential business risks by ensuring our delivery truck drivers remain focused on their driving."

SaverOne Presents Results & Business Update for the First Half of 2022

Retrieved on: 
Thursday, September 8, 2022
COVID-19, CEO, Technology, Safety, Prospectus, Research, Insurance, Risk, U.S. Securities and Exchange Commission, Company, Student, Saudi Readymix Concrete Company, Nasdaq, Government, Part, Death, OEM, National Highway Traffic Safety Administration, Public, Cellcom, Intellectual property, Public expenditure, Bank, Income, Security (finance), Solution, Accident, UTI, Patent, School, Drink, TASE, Private Securities Litigation Reform Act, New England News Collaborative, Growth, Transport, Marketing, Aircraft, Cemex, Traction, NIS, First International Bank of Israel, Intention, Regional Council, Environment, Isuzu, Forward-looking statement, Renewable energy, Mobile phone, Online gambling, Electric battery, EU, Keshet, Insulin aspart

PETAH TIKVAH, Israel , Sept. 8, 2022 /PRNewswire/ -- SaverOne 2014 Ltd. (Nasdaq: SVRE, TASE: SVRE), a technology company engaged in transportation safety solutions, today presented its results for the first half of 2022 and recent business updates. 

Key Points: 
  • PETAH TIKVAH, Israel, Sept. 8, 2022 /PRNewswire/ -- SaverOne 2014 Ltd. (Nasdaq: SVRE, TASE: SVRE), a technology company engaged in transportation safety solutions, today presented its results for the first half of 2022 and recent business updates.
  • Commented Ori Gilboa, CEO of SaverOne, "The past few months have been exceptionally active for SaverOne.
  • As of June 30, 2022, SaverOne had NIS 41 million (approximately $11.7 million) in cash and cash equivalents and short-term bank deposits.
  • Many factors could cause SaverOne's actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements.

CivicaScript™ Announces Launch of its First Product, Creating Significant Patient Savings

Retrieved on: 
Wednesday, August 3, 2022
Oncology, Professional Services, Health, Insurance, Managed Care, Pharmaceutical, Biotechnology, Pharmacy, Blue Cross, Drug, Prednisone, Health, Blue Shield, Face, PBM, Tablet, Partnership, Patient, Insulin lispro, Insurance, Blue Cross Blue Shield Association, Intermountain Healthcare, Prostate cancer, Sale, Welfare, Insulin aspart, Health Care Service Corporation, CEO, Medication, BCBS, Civica, FDA, Medicare, Prescription, Insulin, Medicare Part D, Dietary supplement, Health insurance, Pharmaceutical industry, Insulin glargine

Starting today, CivicaScript will offer abiraterone 250 mg for sale to pharmacies for $160 per bottle of 120 tablets typically a months supply.

Key Points: 
  • Starting today, CivicaScript will offer abiraterone 250 mg for sale to pharmacies for $160 per bottle of 120 tablets typically a months supply.
  • Abiraterone was chosen by CivicaScriptmembers as a priority generic medicine based on its high list price from other manufacturers and significant patient need for the product.
  • This is a proud day for CivicaScript as we advance our mission to make generic medicines affordable and available to everyone, said CivicaScript President Gina Guinasso.
  • CivicaScript then works with like-minded payors, PBMs and pharmacies across the country who pass along the cost savings to their customers.

SaverOne Reports Five New Agreements with Leading Companies and Growing Market Traction

Retrieved on: 
Friday, July 8, 2022
Insurance, Transport, Aircraft, Drink, CEO, Research, COVID-19, Public expenditure, Company, Intellectual property, TASE, U.S. Securities and Exchange Commission, Accident, Prospectus, Forward-looking statement, Cellcom, OEM, Environment, Private Securities Litigation Reform Act, Technology, Nasdaq, Risk, Solution, Patent, Government, Safety, Intention, Security (finance), Mobile phone, Insulin aspart, EU

PETAH TIKVAH, Israel, July 8, 2022 /PRNewswire/ -- SaverOne 2014 Ltd. (Nasdaq: SVRE, TASE: SVRE)("SaverOne" or the "Company"),a technology company engaged in transportation safety solutions, today announced new pilot agreements with some of Israel's leading companies including the Israeli branches of leading global companies, building on the Company's existing strong market traction.

Key Points: 
  • PETAH TIKVAH, Israel, July 8, 2022 /PRNewswire/ -- SaverOne 2014 Ltd. (Nasdaq: SVRE, TASE: SVRE)("SaverOne" or the "Company"),a technology company engaged in transportation safety solutions, today announced new pilot agreements with some of Israel's leading companies including the Israeli branches of leading global companies, building on the Company's existing strong market traction.
  • These agreements follow earlier pilots with leading companies including Osem-Nestle, Kimberly Clark Israel, Redimix, Brimag, Mifalei Tovala, H.Y.
  • "We continue to build momentum in expanding our customer base," commented Ori Gilboa, CEO of SaverOne.
  • Continued Mr. Gilboa,"Furthermore, as part of our global strategy, many of our agreements are with the local Israeli branches of international companies.

Biolexis and Akston Biosciences Announce Encouraging Top-Line Results from Phase II/III Trial of their Thermostable 2nd Gen COVID-19 Vaccine

Retrieved on: 
Friday, June 24, 2022
COVID-19, Research, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Process, Research, Immortalised cell line, STAR, COVID-19, Delta, Company, Longevity, Volunteering, Serum, Seroconversion, ANVISA, Vaccine, EUA, Stelis, Efficiency, WHO, RNA transfection, Fahrenheit, BSE, Population, Immunization, UK, Omicron, GMP, PD, National Stock Exchange of India, Merck, USFDA, Martek Biosciences Corporation, Insulin glargine, Insulin, Global, Diabetes, CEO, DPH, Peptide, Insulin lispro, Immunoglobulin G, Insulin aspart, Partnership, Technology, Temperature, Merck & Co., Leadership, Stride, SmartCell Technology, National Stock Exchange, Porantha Veeda Puguntha Veeda, CDMO, COVID-19 vaccine, Maintenance, Developing country, Safety, Immunity, Pharmaceutical industry, Fine chemical, Phase

The results will be submitted as a prime vaccine in India for Emergency Use Authorization (EUA).

Key Points: 
  • The results will be submitted as a prime vaccine in India for Emergency Use Authorization (EUA).
  • Akston and Strides group have already signed a licensing, manufacturing, and commercialization agreement to launch this vaccine worldwide as AmbiVax-CTM.
  • The vaccine is a reliable, accessible alternative in these regions, allowing immunization and longevity of immunity with the boosters against the Covid variants of concern.
  • Biolexis Private Limited (Biolexis) is an emerging biotech and vaccine company capable of developing and commercializing products for the Global markets.